A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Sonidegib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 10 Nov 2014 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2020, as reported by ClinicalTrials.gov.
- 10 Nov 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.